Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

doi:10.1016/j.jdcr.2017.09.007

Case Reports

. 2018 Jan 16;4(2):129-131.

doi: 10.1016/j.jdcr.2017.09.007. eCollection 2018 Mar.

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

Raphael Reinhard^{1

2}, Christoffer Gebhardt^{1

2}, Nolwenn Maurier¹, Lionel Larribère^{1

2}, Azadeh Orouji¹, Jochen Utikal^{1

2}

Affiliations

¹ Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.
² Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

PMID: 29387762
PMCID: PMC5789521
DOI: 10.1016/j.jdcr.2017.09.007

Case Reports

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

Raphael Reinhard et al. JAAD Case Rep. 2018.

. 2018 Jan 16;4(2):129-131.

doi: 10.1016/j.jdcr.2017.09.007. eCollection 2018 Mar.

Authors

Raphael Reinhard^{1

2}, Christoffer Gebhardt^{1

2}, Nolwenn Maurier¹, Lionel Larribère^{1

2}, Azadeh Orouji¹, Jochen Utikal^{1

2}

Affiliations

¹ Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.
² Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

PMID: 29387762
PMCID: PMC5789521
DOI: 10.1016/j.jdcr.2017.09.007

No abstract available

Keywords: BRAF; MEK; melanoma; metastases; targeted therapy.

PubMed Disclaimer

Figures

**Fig 1**
A, Multiple verrucous epidermotropic melanoma metastases on the left leg/lower abdomen before therapy and B, 2 months after CO₂ laser therapy and topical imiquimod therapy.

**Fig 2**
Histology of epidermotropic melanoma metastases. (A, Hematoxylin-eosin stain; B, anti-S100B stain.)

See this image and copyright information in PMC

References

1. Ascierto P.A., McArthur G.A., Dréno B. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260. - PubMed
1. Long G.V., Stroyakovskiy D., Gogas H. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451. - PubMed
1. Long G.V., Stroyakovskiy D., Gogas H. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. - PubMed
1. Stadler S., Weina K., Gebhardt C., Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci. 2015;60(1):83–88. - PubMed
1. Roesch A., Paschen A., Landsberg J., Helfrich I., Becker J.C., Schadendorf D. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. Eur J Cancer. 2016;59:109–112. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Ascierto P.A., McArthur G.A., Dréno B. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260. - PubMed

[2] Ascierto P.A., McArthur G.A., Dréno B. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260. - PubMed

[3] Long G.V., Stroyakovskiy D., Gogas H. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451. - PubMed

[4] Long G.V., Stroyakovskiy D., Gogas H. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451. - PubMed

[5] Long G.V., Stroyakovskiy D., Gogas H. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. - PubMed

[6] Long G.V., Stroyakovskiy D., Gogas H. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. - PubMed

[7] Stadler S., Weina K., Gebhardt C., Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci. 2015;60(1):83–88. - PubMed

[8] Stadler S., Weina K., Gebhardt C., Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci. 2015;60(1):83–88. - PubMed

[9] Roesch A., Paschen A., Landsberg J., Helfrich I., Becker J.C., Schadendorf D. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. Eur J Cancer. 2016;59:109–112. - PubMed

[10] Roesch A., Paschen A., Landsberg J., Helfrich I., Becker J.C., Schadendorf D. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. Eur J Cancer. 2016;59:109–112. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

Affiliations

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

Authors

Affiliations

Figures

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials